Medscape1d
Anti-Factor XI Anticoagulants: Breakthrough or Bust?
The OCEANIC-AF trial has raised concerns about factor XI inhibitors. Should physicians still bet on this class of ...
Le Lézard5d
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study confirmed that TAH3311 is bioequivalent ...
Morningstar5d
TAHO Pharmaceuticals Reports Positive Results from Pivotal Study of TAH3311, the First Oral Dissolving Film Anticoagulant
TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban ... of deep vein thrombosis or ...
Healio11d
Rivaroxaban tied to higher bleeding rates vs. low-dose aspirin
In a systematic review and meta-analysis of trials of non-vitamin K oral anticoagulants vs. single antiplatelet therapy, ...
EurekAlert!11d
Bleeding risk with apixaban and dabigatran similar to aspirin
A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...